2025 wasn’t just another year in health—it was a turning point. From TikTok trends shaping gut health conversations to WHO guidelines rewriting obesity care, and AI quietly changing how patients search for answers, the landscape shifted fast and kept us talking about health non-stop. The biggest health conversations of 2025 were ubiquitous. For communicators, the challenge wasn’t just keeping up—it was staying trusted as a source of evidence-based information.
So, what are the key lessons to take home, and how do we turn them into smarter strategies for a healthier 2026?
Ultra-Processed Foods (UPFs): Evidence sharpened, scrutiny intensified
Key highlights: The Lancet’s three-paper series linked high UPF intake to increased risk across multiple chronic conditions—obesity, diabetes, cardiovascular disease, depression, even all-cause mortality. Authors called for bold, systemic action: taxes, marketing restrictions, front-of-pack warnings. Their warning? Voluntary reformulation alone won’t cut it.
2026 focus for comms:
- Think about the ‘why’: acknowledge the Lancet signal while explaining why risks arise—think energy density, additives, and displacement of whole foods.
- Reformulation and transparency should be part of a long-term health mission, not a defensive move.
- Need to prepare for policy-led changes and map stakeholder expectations early.
Gut health went mainstream
Key highlight: Gut health became a cultural phenomenon—fuelled by TikTok (#GutTok >1.2B views) and reinforced by science linking microbiome diversity to immunity, mood, and metabolic health.
2026 focus for comms:
- Time to replace “miracle” language with everyday rituals and plain-English science.
- Use credible voices and visual explainers to decode mechanisms without overclaiming.
- Build educational assets that retailers and influencers can embed.
GLP-1s: Clinical breakthrough, policy lag
Key highlights: WHO issued its first guideline endorsing GLP-1 medicines for long-term obesity care (conditional on affordability and system readiness) and added them to its Essential Medicines List. UK debate focused on pricing reform and equity, with think tanks proposing pooled procurement and outcomes-based models—none fully implemented yet.
2026 focus for comms:
- Position brands as partners, not just product suppliers.
- Support HCPs and patients with nutrition guidance during and after treatment.
- Explain the bigger picture: how these medicines improve health outcomes and reduce long-term costs for the system.
Patients are searching with AI now—are you findable and trusted?
Key highlight: AI-powered summaries became a default feature in search. Surveys show most consumers encounter them and find them “somewhat reliable,” but trust hinges on cited sources.
2026 focus for comms:
- Make your content AI-friendly.
- Strengthen earned content—expert commentary, reputable media—because AI amplifies what it trusts.
- Audit AI answers quarterly and correct inaccuracies.
Women’s health: A priority at last?
Key highlight: NHS England made the morning-after pill free at nearly 10,000 pharmacies—hailed as the biggest sexual health service change since the 1960s.
2026 focus for comms:
- Support pharmacies with discreet, shareable assets and myth-busting content.
- Join the dots with wider care—contraception, STI testing, ongoing sexual health support.
Prostate cancer screening: Divided opinion—and now a role model for change
Key highlights: The UK National Screening Committee’s draft recommendation advises against universal PSA screening, recommending targeted screening for men aged 45–61 with BRCA1/2 variants. Meanwhile, a £42m TRANSFORM trial has begun, combining PSA, rapid MRI, and genetic markers to fine-tune screening protocols.
New catalyst: In December, King Charles III revealed that early detection allowed him to reduce treatment in 2026—and urged the public to attend screenings, helping to shatter fear and embarrassment and frame early detection as an act of strength.
Focus for comms:
- Champion this reframed perception of screening—responsibly
- Close the equity gap. Brands can lead with purpose highlighting the higher risk for black men and those with family history, creating culturally sensitive campaigns and partnering with key stakeholders.
- Prepare for the next wave of evidence as the TRANSFORM trial will shape future policy.
Pricing and the UK life-sciences climate: Communicating amid uncertainty
2025 highlight: 2025 was tough for UK pharma. Merck scrapped plans for a £1bn research hub, and AstraZeneca shifted billions to the US. A new UK–US trade deal now links tariff relief to higher NHS prices, and a working group is exploring fresh ideas like outcomes-based pricing and incentives to keep R\&D in Britain.
Focus for comms:
- Prepare for change, as policy could shift mid-year
- Explore more constructive narratives: fair pricing models, UK-based clinical trials, and public–private partnerships.
- Show why it matters: how smart pricing leads to faster access to medicines and supports UK innovation and jobs.
Three cross-cutting actions for 2026 for health communicators, from audient health
- Irrespective of therapy area or discipline, earning trust in the age of AI is paramount. In this context, treating referenced content and earned media as your discoverability engine-for machines as well as people is clearly a strategic must.
- Simplify complexity and break down abstract claims into stepped approaches. Whether UPFs, gut health or GLP-1s a shift of focus to small daily actions and clear care pathways supports adoption and sustainability.
- Narrate policy with empathy. On screening and pricing, consider your audience and explain why decisions look the way they do, what evidence will move them, and how you’ll help stakeholders adapt.
Final thoughts? 2025 reminded us that health communication isn’t just about facts—it’s about framing those facts in ways that feel human, actionable, and trustworthy. As we step into 2026, the brands that listen first and speak with clarity will lead the conversation.
